# OnCo record radium-223 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/radium-223/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "radium-223" ;
  schema:name "Radium-223 dichloride"@en ;
  schema:description "Radium-223 was the first alpha-emitting drug ever approved (2013). It homes to bone like calcium and treats prostate cancer that has spread only to bone."@en ;
  schema:url <https://onco.cc/drugs/radium-223/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Radium-223> ;
  owl:sameAs <http://www.wikidata.org/entity/Q18888805> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Radium-223%20dichloride>, <https://www.nice.org.uk/guidance/ta412>, <https://doi.org/10.1016/j.annonc.2026.02.009> ;
  onco:status "approved" ;
  onco:modality "Targeted alpha therapy (bone-seeking)" ;
  schema:alternateName "Xofigo" ;
  onco:approval "US 2013: Symptomatic bone-metastatic CRPC without visceral disease" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:companies <https://onco.cc/companies/bayer/> ;
  onco:terms <https://onco.cc/terms/alpha-vs-beta/>, <https://onco.cc/terms/prostate-crpc-sequencing/>, <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/alsympca/> .